Katharine Phillips joins host Catherine Glass to explore how brain circuitry, heritability, and visual processing abnormalities contribute to body dysmorphic disorder. Drawing on decades of clinical research, she discusses chronicity, recovery patterns, and how surgeons can better identify patients seeking aesthetic procedures for BDD. This episode unpacks the neurobiological and behavioural roots behind the disorder.

Timestamps:

01:05 – Clinical features

02:25 – Neurobiology

05:10 - Interventions

08:50 – Longitudinal research

11:10 – Patient insight

In this rapid-fire episode, Katharine Phillips answers essential questions about body dysmorphic disorder (BDD), from early signs and common misdiagnoses to key medications, childhood prevalence, and what truly distinguishes BDD from everyday appearance concerns. A perfect 5-minute listen for clinicians and curious minds wanting a fast, high-impact overview of BDD.

Rockstroh examines emerging challenges in HIV care, including COVID-19 and mpox, novel therapies, and lessons from Europe's care model. Explore the possibilities of shifting from disease management towards long-term remission and functional cure.

Timestamps:

00:00 – Introduction

00:45 – COVID-19 lessons

05:02 – Mpox challenges

07:42 – Novel therapies

12:56 – Improving care

15:39 – Remission or cure?

From HIV/hepatitis co-infections to haemophiliac cohorts, Rockstroh shares strategies for managing complex patient populations. Discover how antiretroviral therapy, multidisciplinary care, and lifestyle interventions work together to optimise outcomes.

Timestamps:

00:00 – Introduction

01:17 – HIV/hepatitis co-infection

05:43 – Cardiovascular risk

08:06 – Haemophiliac cohorts

11:47 – Multidisciplinary care

AMJ Podcast | Episode 4

Capivasertib in the Clinic: Strategies to Manage Adverse Events

This content was funded by AstraZeneca, and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information, including Patient Information when making treatment decisions.

Indication and Usage

Capivasertib (TRUQAP®) in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Description

In this practical, case-based discussion, a breast oncology pharmacist and nurse practitioner walk through how they anticipate and manage the most common adverse events seen with capivasertib in HR-positive/HER2-negative advanced breast cancer.

Drawing on real-world clinic workflows, they share stepwise approaches to counseling, prophylaxis, and early intervention for diarrhea, rash, and hyperglycemia, including when to escalate monitoring or treatment and how to coordinate roles across the care team.

You'll hear communication scripts, tips for using tools such as stool diaries and home glucometers, and strategies to keep patients on therapy safely and confidently.

Chapters

• 00:00 – 03:24 | Introduction
• 03:24 – 05:18 | When to consider capivasertib
• 05:18 – 08:51 | Introducing adverse events
• 08:51 – 16:18 | Diarrhea management
• 16:18 – 20:35 | Rash management
• 20:35 – 25:07 | Hyperglycemia management
• 25:07 – 27:31 | Care team best practices
• 27:31 – 31:18 | Top Tips & Takeaways

Speakers:

Heather Moore – Breast Oncology Pharmacist, Duke University Medical Center

Sarah Donohue – Breast Oncology Nurse Practitioner, UCSF Health Breast Care Center

Select Safety Information About capivasertib (TRUQAP®) tablets

TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.

Serious adverse reactions include hyperglycemia, including diabetic ketoacidosis and fatal outcomes; diarrhea; and cutaneous adverse reactions. Monitor fasting glucose and hemoglobin A1C levels regularly. May cause fetal harm when administered to a pregnant woman. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), increased fasting glucose (37%), nausea and fatigue (35% each), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).

Please see full Prescribing Information, including Patient Information for TRUQAP.